Interfibio attends the PoCCardio General Assembly Meeting to drive Innovations in Personalised Medicine for Cardiovascular Care
On the 29th and 30th of October, Interfibio joined the PoCCardio General Assembly Meeting to further its contributions to a ground-breaking initiative in personalised medicine: the development of an advanced Point-of-Care (PoC) tool for high-risk cardiovascular patients. The project focuses on refining personalised treatment strategies to improve the prognosis and quality of life for those affected by cardiovascular diseases (CVDs), the leading cause of death globally.
The mission of PoCCardio is to empower healthcare providers with accessible, stratified treatment options through a PoC tool that can measure specific proteomic and genetic markers indicative of cardiovascular risk. Traditionally, identifying such markers has required costly and complex laboratory analyses that are accessible only in specialized, tertiary healthcare facilities. PoCCardio's innovative PoC tool, initially developed under the HORIZON 2020 initiative, leverages cutting-edge lab-on-a-chip (LoC) and microfluidic technology to overcome this barrier. By enabling the measurement of qualified biomarkers and polymorphisms from a simple finger prick blood sample, the tool allows clinicians in low-threshold settings to more effectively classify and monitor high-risk CVD patients.
The project will conduct a prospective, randomized, multinational clinical trial to validate these biomarkers and the PoC tool. Participants will be assigned either standard pharmacological care or a tailored, intensified treatment protocol based on their biomarker profiles, using only pre-approved pharmaceuticals. This approach, powered by advanced AI-based analysis, is expected to provide insights into predictive factors for primary and secondary outcomes. The data will be critical for supporting regulatory decisions, including the approval of companion diagnostics and targeted drug prescriptions.
Interfibio's Role: Innovating with Aptamer Selection
In collaboration with five academic partners and two SMEs, Interfibio plays a key role in developing the PoC tool's biosensing capabilities. Interfibio's expertise in aptamer technology will be instrumental in selecting suitable aptamers and creating aptamer pairs for sandwich assays. This contribution is essential to the tool's biomarker-detection process, as aptamers will allow highly specific and sensitive recognition of relevant CVD biomarkers.
Further strengthening the project is our specialised knowledge in genomic biosensors enabiling the PoC tool to achieve a comprehensive, biomarker-driven approach to personalised CVD treatment. Interfibio's involvement in the PoCCardio project underscores its commitment to advancing personalised medicine.
Paving the Way for Regulatory and Clinical Advances in CVD Treatment
The insights generated from PoCCardio's clinical validation trial will serve as a cornerstone for shaping future regulatory frameworks and clinical guidelines. By demonstrating the efficacy of biomarker-driven personalised treatment, the project seeks to set new standards for companion diagnostics and medication prescription for high-risk cardiovascular patients. The anticipated outcomes include improved treatment efficacy, lower healthcare costs, and enhanced patient outcomes, all achieved through an accessible and streamlined PoC-based approach.
Elements relacionats
Compartir
